These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37160959)

  • 21. Discriminative stimulus effects of morphine and oxycodone in the absence and presence of acetic acid in male and female C57Bl/6 mice.
    Neelakantan H; Ward SJ; Walker EA
    Exp Clin Psychopharmacol; 2015 Aug; 23(4):217-27. PubMed ID: 26237319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurophysiological response properties of medullary pain-control neurons following chronic treatment with morphine or oxycodone: modulation by acute ketamine.
    Viisanen H; Lilius TO; Sagalajev B; Rauhala P; Kalso E; Pertovaara A
    J Neurophysiol; 2020 Sep; 124(3):790-801. PubMed ID: 32755331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics.
    Raehal KM; Bohn LM
    Neuropharmacology; 2011 Jan; 60(1):58-65. PubMed ID: 20713067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic opioid exposure differentially modulates oxycodone self-administration in male and female rats.
    Mavrikaki M; Lintz T; Constantino N; Page S; Chartoff E
    Addict Biol; 2021 May; 26(3):e12973. PubMed ID: 33078503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abuse liability of oxycodone as a function of pain and drug use history.
    Comer SD; Sullivan MA; Vosburg SK; Kowalczyk WJ; Houser J
    Drug Alcohol Depend; 2010 Jun; 109(1-3):130-8. PubMed ID: 20079977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats.
    Zamarripa CA; Patel TR; Williams BC; Pareek T; Schrock HM; Prisinzano TE; Freeman KB
    Behav Pharmacol; 2020 Dec; 31(8):792-797. PubMed ID: 32804774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine D
    You ZB; Bi GH; Galaj E; Kumar V; Cao J; Gadiano A; Rais R; Slusher BS; Gardner EL; Xi ZX; Newman AH
    Neuropsychopharmacology; 2019 Jul; 44(8):1415-1424. PubMed ID: 30555159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex differences in responsiveness to the prescription opioid oxycodone in mice.
    Collins D; Reed B; Zhang Y; Kreek MJ
    Pharmacol Biochem Behav; 2016 Sep; 148():99-105. PubMed ID: 27316549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers.
    Zacny JP; Gutierrez S
    Psychopharmacology (Berl); 2011 Dec; 218(3):471-81. PubMed ID: 21603891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strain and sex-related behavioral variability of oxycodone dependence in rats.
    Doyle MR; Martinez AR; Qiao R; Dirik S; Di Ottavio F; Pascasio G; Martin-Fardon R; Benner C; George O; Telese F; de Guglielmo G
    Neuropharmacology; 2023 Oct; 237():109635. PubMed ID: 37327971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Who is HOT and who is LOT? Detailed characterization of prescription opioid-induced changes in behavior between 129P3/J and 129S1/SvlmJ mouse substrains.
    Szumlinski KK; Coelho MA; Tran T; Stailey N; Lieberman D; Gabriella I; Swauncy I; Brewin LW; Ferdousian S
    Genes Brain Behav; 2020 Jun; 19(5):e12609. PubMed ID: 31489753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antinociceptive effect of oxycodone in diabetic mice.
    Nozaki C; Saitoh A; Tamura N; Kamei J
    Eur J Pharmacol; 2005 Nov; 524(1-3):75-9. PubMed ID: 16256106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone.
    Graziani M; Nisticò R
    Pharmacol Res; 2016 Jun; 108():31-38. PubMed ID: 27107788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine D
    de Guglielmo G; Kallupi M; Sedighim S; Newman AH; George O
    Front Behav Neurosci; 2019; 13():292. PubMed ID: 31992976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.
    Jones JD; Sullivan MA; Manubay J; Vosburg SK; Comer SD
    Neuropsychopharmacology; 2011 Jan; 36(2):411-22. PubMed ID: 20980992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGR3 regulates opioid-related nociception and motivation in male rats.
    Mitra S; Thomas SA; Martin JA; Williams J; Woodhouse K; Chandra R; Li JX; Lobo MK; Sim FJ; Dietz DM
    Psychopharmacology (Berl); 2022 Nov; 239(11):3539-3550. PubMed ID: 36098762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.
    Stoops WW; Hatton KW; Lofwall MR; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2010 Oct; 212(2):193-203. PubMed ID: 20665209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.
    Burness CB; Keating GM
    Drugs; 2014 Mar; 74(3):353-75. PubMed ID: 24452879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of oxycodone and diazepam alone and in combination on operant nociception.
    Leonard MZ; Kangas BD
    Behav Pharmacol; 2020 Apr; 31(2&3):168-173. PubMed ID: 31972623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.